Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.


Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.

Keywords: ACS; ADP; CABG; CAD; CI; HPR; HR; LPR; MI; OR; P2Y(12) reaction units; PCI; PFT; PR; PRI; PRU; ROC; ST; TIMI; Thrombolysis In Myocardial Infarction; VASP-P; acute coronary syndrome(s); adenosine diphosphate; bleeding; confidence interval; consensus; coronary artery bypass graft; coronary artery disease; hazard ratio; high platelet reactivity to adenosine diphosphate; ischemia; low platelet reactivity to adenosine diphosphate; myocardial infarction; odds ratio; percutaneous coronary intervention; platelet function testing/test; platelet reactivity; platelet reactivity index; receiver-operating characteristic; stent thrombosis; vasodilator-stimulated phosphoprotein-phosphorylation.

Publication types

  • Consensus Development Conference

MeSH terms

  • Acute Coronary Syndrome / therapy
  • Adenosine Diphosphate / therapeutic use*
  • Angioplasty, Balloon, Coronary*
  • Blood Platelets / drug effects
  • Coronary Artery Disease / therapy
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / prevention & control
  • Hemorrhage / etiology*
  • Humans
  • Myocardial Ischemia / etiology*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Function Tests*
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Receptors, Purinergic P2Y12 / drug effects
  • Risk Assessment
  • Risk Factors
  • Stents / adverse effects


  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Adenosine Diphosphate